Emodin Sensitizes Cervical Cancer Cells to Vinblastine by Inducing Apoptosis and Mitotic Death
Overview
Chemistry
Molecular Biology
Authors
Affiliations
In recent years, studies on the effects of combining novel plant compounds with cytostatics used in cancer therapy have received considerable attention. Since emodin sensitizes tumor cells to chemotherapeutics, we evaluated changes in cervical cancer cells after its combination with the antimitotic drug vinblastine. Cellular changes were demonstrated using optical, fluorescence, confocal and electron microscopy. Cell viability was assessed by MTT assay. The level of apoptosis, caspase 3/7, Bcl-2 protein, ROS, mitochondrial membrane depolarization, cell cycle and degree of DNA damage were analyzed by flow cytometry. The microscopic image showed indicators characteristic for emodin- and vinblastine-induced mitotic catastrophe, i.e., multinucleated cells, giant cells, cells with micronuclei, and abnormal mitotic figures. These compounds also increased blocking of cells in the G2/M phase, and the generated ROS induced swelling and mitochondrial damage. This translated into the growth of apoptotic cells with active caspase 3/7 and inactivation of Bcl-2 protein and active ATM kinase. Emodin potentiated the cytotoxic effect of vinblastine, increasing oxidative stress, mitotic catastrophe and apoptosis. Preliminary studies show that the combined action of both compounds, may constitute an interesting form of anticancer therapy.
Wang Q, Zhang J Transl Cancer Res. 2025; 14(1):286-295.
PMID: 39974389 PMC: 11833387. DOI: 10.21037/tcr-24-1260.
Trybus W, Trybus E, Obarzanowski M, Krol T Sci Rep. 2025; 15(1):5252.
PMID: 39939343 PMC: 11822151. DOI: 10.1038/s41598-025-89847-8.
Thuy P, Jang T, Moon E Int J Mol Sci. 2024; 25(19).
PMID: 39408701 PMC: 11477320. DOI: 10.3390/ijms251910369.
Advances in the mechanism of emodin-induced hepatotoxicity.
Wang Y, Zhao M, Li B, Geng X Heliyon. 2024; 10(13):e33631.
PMID: 39027614 PMC: 11255441. DOI: 10.1016/j.heliyon.2024.e33631.
Sabanayagam R, Krishnamoorthy S, Anbuselvam M, Muruganantham B, Muthusami S Med Oncol. 2023; 40(12):357.
PMID: 37964051 DOI: 10.1007/s12032-023-02223-2.